Carboplatin and etoposide (CE) chemotherapy in patients with recurrent or progressive oligodendroglial tumors

Luciano Scopece, Enrico Franceschi, Giovanna Cavallo, Anna Paioli, Gabriele Paioli, Rosa Conforti, Emanuela Palmerini, Carlotta Berzioli, Federica Spagnolli, Roberta Degli Esposti, Lucio Crinò

Research output: Contribution to journalArticlepeer-review


Background: Oligodendroglial tumors are rare and chemosensitive diseases; but the overall results with current chemotherapy regimens cannot be considered satisfactory and other active treatments are necessary. We decided to determine the efficacy and toxicity profile of the carboplatin and etoposide (CE) regimen in this setting. Methods: In this phase II trial we evaluated the response rate of first or second line CE regimen (Carboplatin AUC 5 on day 1 and Etoposide 120 mg/m 2 on days 1-3 every 28 days) in patients with recurrent/progressive oligodendroglial tumors. Results: Thirty-two patients were enrolled. Median age was 42 years (range 22-66); median ECOG PS was 0 (range 0-2); 9 patients had oligodendroglioma, 3 patients had oligoastrocytoma, 11 patients had anaplastic oligodendroglioma, 9 patients had anaplastic oligoastrocytoma. CE regimen showed a response rate of 46.9% with 5 complete responses (15.6%) and 10 partial responses (31.3%). Eleven patients (34.4%) had stable disease. Median time to progression was 8 months, progression-free survivals at 6 and 12 months were 80% and 46.9%, respectively. Toxicity was mainly hematological, with grade 3-4 neutropenia in 5 (15.6%) patients. Conclusions: In this trial CE regimen has shown relevant activity with a favourable safety profile.

Original languageEnglish
Pages (from-to)299-305
Number of pages7
JournalJournal of Neuro-Oncology
Issue number3
Publication statusPublished - Sep 2006


  • Carboplatin
  • Chemotherapy
  • Etoposide
  • Oligodendroglial tumors

ASJC Scopus subject areas

  • Clinical Neurology
  • Cancer Research
  • Oncology
  • Neuroscience(all)


Dive into the research topics of 'Carboplatin and etoposide (CE) chemotherapy in patients with recurrent or progressive oligodendroglial tumors'. Together they form a unique fingerprint.

Cite this